Oncology

FWMOH and AON's new radiation oncology division is disrupting Indiana's cancer care market by bypassing hospital fees and democratizing advanced treatments.

As liver cancer deaths near 31,000 annually, a new House resolution and AI-driven blood tests aim to fix a broken screening system for high-risk patients.

ViroMissile's intravenously delivered oncolytic virus, IDOV-2, shows early signs of stable disease in Phase I, hinting at a breakthrough for metastatic cancers.

A new peer-reviewed study validates RenovoRx's targeted catheter platform, offering a strategic bridge as the company approaches its 2027 Phase III readout.

Los Angeles Cancer Network's rebrand to Oncura Health signals a massive shift in Southern California, leveraging private capital to decentralize cancer care.

With over 700,000 annual deaths, liver cancer is a global crisis. Yet 60% of cases are preventable. We explore the gap between innovation and patient access.

Rakovina Therapeutics is teaming up with Celvion to leverage real-world AI data, aiming to bypass clinical hurdles and de-risk its ATR inhibitor pipeline.

Pliant Therapeutics taps veteran oncologist Dr. David Raben as CMO to steer its targeted ICI-refractory cancer program toward crucial 2027 clinical milestones.

As prostate cancer rates climb, top oncologists and investors converge to discuss how AI, immunotherapy, and strategic capital are redefining treatment.

NuCana's new European patent for its cancer drug NUC-7738 strengthens its global IP moat, backing its clinical push against PD-1 resistant melanoma into 2029.

AstraZeneca’s $2 billion investment in Summit Therapeutics signals a structural shift in cancer care, uniting bispecifics and ADCs to dethrone incumbents.

Veracyte's Decipher test isn't just guiding prostate cancer treatment; its whole-transcriptome engine is building an unassailable commercial diagnostics moat.

J&J's CARVYKTI shows half of early-line myeloma patients achieve five-year remissions. But does a functional cure justify the severe upfront risks?

Institutional investors and GCC healthcare giants are treating the global women's health gap not as a niche, but as a $1 trillion macroeconomic catalyst.

Fuse Oncology expands its clinical platform to the full care team, aiming to slash cancer treatment wait times from weeks to days while easing staff burnout.

Marathon Fusion proposes a novel supply chain hack using a stable precursor to solve the multi-decade shortage of a promising cancer-treating radioisotope.

Türkiye’s first proton therapy center at Çam ve Sakura City Hospital proves that shrinking medical tech is the key to expanding global cancer care access.

A €12M Series A for German biotech ViferaXS highlights a strategic shift in European sovereign funding and the rise of the tech-bio equity playbook.

Amid a severe shortage of medical dosimetrists, Radformation’s model-free VMAT automation could redefine the economics and workflow of radiation oncology.

Fennec Pharmaceuticals unveils compelling trial data showing its therapy prevents permanent hearing loss in children undergoing life-saving chemotherapy.